Dose-response Study of Paricalcitol Injection in Chronic Kidney Disease Patients Receiving Hemodialysis

- Diagnosed with chronic kidney disease receiving hemodialysis 3 times a week for at least 3 months prior to obtaining the informed consent and scheduled to be receiving the same hemodialysis during the study period. - Using dialysate with constant concentration of calcium for 4 weeks prior to obtaining informed consent and phosphate binder with constant dose regimen for 2 weeks prior to obtaining informed consent. - Intact parathyroid hormone level (iPTH) ≥ 300 pg/mL - Calcium (adjusted) 8.4-10.2 milligrams/deciliter (mg/dL) - Phosphorus ≤ 6.5 mg/dL - Age ≥ 20 years

- History of allergic reaction or significant sensitivity to vitamin D or vitamin D related compounds - Parathyroidectomy or ethanol infusion within past year - Progressive malignancy or clinically significant hepatic diseases, severe cerebral/cardiovascular diseases, severe hypertension, or uncontrolled diabetes mellitus - Drug or alcohol abuse within past 6 months - Taking calcitonin, maintenance intravenous or oral glucocorticoids, cinacalcet, bisphosphonates, selective estrogen-receptor modulator (SERM), vitamin D compounds (other than study drug), or other drugs that may affect calcium or bone metabolism (other than estrogen or progestin, vitamin K2) - Will need to take chronic dose (≥ 2 consecutive weeks) of cytochrome P450 (CYP3A) inhibitors (e.g., clarithromycin, grapefruit products) or inducers (e.g., carbamazepine, rifampicin) - Taking aluminum containing products (2 weeks prior to consent)